Hyperbaric oxygen treatment on keloid tumor immune gene expression | Canada Hyperbarics Skip to main content
Study Chin Med J (Engl) 2021

Hyperbaric oxygen treatment on keloid tumor immune gene expression

Wang C, Shan M, Liu H, Hao Y, Song K, Wu H, et al. — Chin Med J (Engl), 2021

Tier 2, Indexed

Automatically imported from PubMed based on relevance criteria.

Summary

What Researchers Did

Chinese researchers gave six keloid patients four HBOT sessions before surgery and compared tumor gene expression and immune cell infiltration against six untreated keloid patients.

What They Found

HBOT reduced inflammatory cell infiltration and changed expression of 395 genes, with 10 hub genes identified including IL-4, IL-6, CD80, and CTLA4. CD4 T cells, particularly activated memory CD4+ T cells, increased significantly in HBOT-treated tissue. Inflammatory markers CD80 and IL-4 were significantly downregulated.

Canadian Relevance

No direct Canadian connection identified.

Study Limitations

With only 6 patients per group and no clinical outcome data, this study provides mechanistic clues but cannot confirm whether immune changes translate into fewer keloid recurrences.

Was this summary helpful?

Study Details

Study Type Study
Category Uncategorised
Source Pubmed
PubMed ID 34553702
Year Published 2021
Journal Chin Med J (Engl)
MeSH Terms Gene Expression; Humans; Hyperbaric Oxygenation; Keloid; Neoplasms; Oxygen

Cite This Study

Share

Find a Canadian Clinic Treating Uncategorised

Browse verified hyperbaric facilities across Canada.

View Canadian Facilities

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.